Risk of diabetes mellitus in HIV-infected patients receiving highly active antiretroviral therapy: A nationwide population-based study. 2018

Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
Department of Internal Medicine, Taichung Veterans General Hospital, Taichung National Cancer Institute, National Health Research Institute, Miaoli Graduate Institute of Clinical Medicine, National Yang-Ming University, Taipei Department of Life Sciences, National Chung Hsing University Department of Public Health, College of Public Health, China Medical University Department of Nursing, Central Taiwan University of Science and Technology Graduate Institute of Public Health, College of Public Health, China Medical University, Taichung Department of Nursing, College of Medicine, National Cheng Kung University and Hospital, Tainan, Taiwan.

Previous studies have shown that the incidence of diabetes mellitus (DM) has increased in human immunodeficiency virus (HIV)-infected patients with long-term exposure to highly active antiretroviral therapy (HAART). However, the factors associated with DM among HIV-infected patients in Asia remain unclear in the HAART era.A nationwide cohort studyData from Taiwan's National Health Insurance Research Database (NHIRD) between 2000 and 2010 were used to investigate the incidence of and factors associated with DM among HIV-infected patients. Propensity score matching was conducted to match 4797 patients receiving HAART (HAART cohort) with 4797 patients not receiving HAART (non-HAART cohort). HAART use was treated as a time-dependent variable in a Cox regression model.HAART cohort had a significantly higher 10-year incidence of DM (7.16%; 95% confidence interval [CI], 4.30%-10.03%) than non-HAART cohort (2.24%; 95% CI, 1.28%-3.20%) (P < .001). After adjusting for age, gender, and comorbidities, receiving HAART was associated with an increased incidence of DM, with a subdistribution hazard ratio (sHR) of 2.39 (95% CI, 1.65-3.45). Hypertension (sHR = 5.27; 95% CI, 3.21-8.65), gout (sHR = 2.39; 95% CI, 1.38-4.16), and hepatitis C virus (HCV) infection (sHR = 2.43; 95% CI, 1.28-4.61) were significantly associated with a higher risk of DM. Sensitivity analyses showed exposure to HAART remained significantly associated with an increased risk of DM, particularly in those without pre-existing hypertension, gout, or HCV infection.Exposure to HAART increased the risk of DM in HIV-infected Taiwanese patients, particularly in those without pre-existing hypertension, gout, or HCV infection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D012737 Sex Factors Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from SEX CHARACTERISTICS, anatomical or physiological manifestations of sex, and from SEX DISTRIBUTION, the number of males and females in given circumstances. Factor, Sex,Factors, Sex,Sex Factor

Related Publications

Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
October 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
February 2010, HIV medicine,
Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
January 2002, Journal of acquired immune deficiency syndromes (1999),
Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
February 2017, Acta clinica Belgica,
Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
January 2005, Antiviral therapy,
Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
November 2002, Journal of acquired immune deficiency syndromes (1999),
Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
December 2004, The Annals of pharmacotherapy,
Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
October 2002, International journal of STD & AIDS,
Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
November 2012, BMC infectious diseases,
Shih Ping Lin, and Chun-Ying Wu, and Chang-Bi Wang, and Tsai-Chung Li, and Nai-Ying Ko, and Zhi-Yuan Shi
March 2001, Chest,
Copied contents to your clipboard!